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Abstract
Replication-competent adenoviruses armed with thymidine kinase (TK) combine the concepts of virotherapy and suicide
gene therapy. Moreover TK-activity can be detected by noninvasive positron emission-computed tomography (PET)
imaging, what could potentially facilitate virus monitoring in vivo. Here, we report the generation of a novel oncolytic
adenovirus that incorporates the Tat8-TK gene under the control of the Major Late Promoter in a highly selective backbone
thus providing selectivity by targeting the retinoblastoma pathway. The selective oncolytic TK virus, termed ICOVIR5-TK-L,
showed reduced potency compared to a non-selective counterpart. However the combination of ICOVIR5-TK-L with
ganciclovir (GCV) induced a potent antitumoural effect similar to that of wild type adenovirus in a preclinical model of
pancreatic cancer. Although the treatment with GCV provoked a reduction in the viral yield, both in vitro and in vivo, a two-
cycle treatment of virus and GCV resulted in an enhanced antitumoral response that correlated with high TK-activity, based
on microPET measurements. Thus, TK-expressing oncolytic adenoviruses can be traced by PET imaging providing real time
information on the activity of the virus and its antitumoral potency can be optimized by GCV dosing.
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Introduction
Arming tumor selective adenoviruses to express a transgene
combines gene therapy and virotherapy and facilitates the
incorporation of complementary or synergistic mechanisms oper-
ating in a unique virus. We have previously shown that the insertion
of the modified form of the herpes simplex virus thymidine kinase
gene, Tat8TK under the control of the major late promoter in the
adenoviral genome AdRGDTat8-TK-L results in a highly potent
replication competent adenovirus when combined with ganciclovir
(GCV) [1]. Tat8TK is an engineered version of TK that
incorporates an eight-amino acid domain derived from the human
immunodeficiency virus Tat protein. We have previously shown
that this fusion protein displays greater cytotoxicity than wild type
TK probably due to protein-transduction capabilities conferred by
the Tat8 domain [2].
The elements of success of a therapeutic virus are based both on
theefficacyinreductionoftumorburdenanditspreferentialactivity
on tumor cells. Thus, replication-selective control of adenoviruses is
fundamental to provide safety to oncolytic virotherapy. Oncolytic
adenoviruses that target the pRB pathway were initially developed
by deletion of the pRB binding site of E1A, generating a mutant
adenovirus unable to dissociate pRB from E2F in quiescent normal
cells, limiting the transcriptional activation of E2 viral genes by E2F,
thus avoiding viral replication [3,4]. Additional modifications such
as the insertion of an RGD peptide in the HI loop and the
introduction of an insulated E2F promoter controlling E1A resulted
in the improved pRB based selective oncolytic adenovirus
ICOVIR-5 [5].
The possibility to non-invasively monitor the tumor or non-
tumor location of a replication competent virus dramatically
improves the quality on the follow-up of a viral therapy and can
provide real-time information on the activity of the injected virus.
Oncolytic adenoviruses expressing the TK gene are susceptible of
being traced by positron emission-computed tomography (PET)
scans. A number of radioactive substrates that can be detected in
PET, based on the capacity of the herpes simplex viral thymidine
kinase to phosphorylate a variety of substrates that can not be
phosphorylated by the mammalian thymidine kinase have been
described [6]. With this technique there are several examples
documenting TK expression in preclinical models both in tumors
[7,8,9] or in normal tissues such as in mouse or non-human
primates liver upon intravenous (i.v.) adenoviral delivery [10,11].
Importantly, TK expression has also been monitored by PET
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with a first-generation adenovirus encoding the TK gene [12].
In this study we have developed a novel oncolytic adenovirus
that incorporate the optimized Tat8-TK gene controlled by the
adenoviral major late promoter in an ICOVIR-5 backbone and
show that the potency of the selective virus, ICOVIR5-TK-L, can
be significantly improved when combined with GCV in pancreatic
tumors. Importantly we show that oncolytic adenoviruses
expressing the TK gene can be monitored by PET and that the
protocol of GCV administration impacts on the TK activity
induced by ICOVIR5-TK-L.
Materials and Methods
Cell Lines
The human pancreatic adenocarcinoma cell lines BxPC-3,
RWP1, PANC-1, NP-9 and NP-18, the A549 human lung cancer
cells; and the HEK293 cells were obtained from the ATCC
(Manasas, Virginia, United States) or from G. Capella ` and FX.
Real Laboratories [13], [14] and cultured as previously described
[15].
Adenovirus construction and infection
Construction of recombinant AdTK, AdTat8-TK and replica-
tion competent Adwt-RGD, AdRGDTat8-TK-L and ICOVIR-5
have been previously described [1,16,17,18,19]. Here we have
generated a novel virus named ICOVIR5-TK-L. The plasmid
pNKFiber RGDTat8TK [1] was digested with NotI and KpnI and
recombined by homologous recombination in yeast with the
plasmid pICOVIR5SwaCAU. This plasmid derives from pI-
COVIR5 [5] by first inserting yeast replication elements in the
plasmid backbone (a centromer CEN6 region modified to
eliminate the SwaI site, an autonomous replicating region, and a
Ura3 gene for selection) and later inserting a SwaI site in the
adenovirus fiber to become a unique site for cut-repair
homologous recombination in yeast. The recombination of the
RGDTat8TK fiber in this plasmid resulted in pICOVIR5-TK-L.
Confirmation of pICOVIR5-TK-L integrity was performed by
analysing the presence of the different DNA elements (E2F
promoter, E1A-D24 deletion, TK and hexon) by PCR and DNA
sequencing. pICOVIR5-TK-L was cut with PacI and transfected
in HEK293 cells to generate ICOVIR5-TK-L which was plaque-
isolated and propagated in A549 cells.
All viruses were purified by standard Caesium Chloride
banding. The physical particle concentration (vp/ml) was deter-
mined by Optical Density reading (OD260) and the plaque forming
units (pfu/ml) were determined on HEK293 cells by the anti-
hexon staining-based method [1].
RT-PCR analysis
RNA was extracted from a panel of cell lines infected with
ICOVIR5-TK-L using TriPure isolation Reagent (Roche Applied
Science, Sant Cugat del Valle `s, Spain). To avoid genomic
contamination RNA samples were treated with DNase (DNA-
free, Ambion, Applied Biosystems, Madrid, Spain) as described by
manufacturer’s protocol. One mg of total RNA from each sample
was reverse transcribed with a Retroscript RT kit (Ambion). Two
ml of cDNA was PCR amplified with four pairs of specific primers
for four different regions: promoter region (E2F-F: 59 CG-
CGTTAAAGCCAATAGGAA 39 and E1A-R2 59 CGGCCAT-
TTCTTCGGTAATA 39), TK (TK59: CTCATCCCGCCGA-
CCT and TK39: CACGACCCGCCGCCCTG), E1A (E1A59:A -
TCGAAGAGGTACTGGCTGA and E1A39: CCTCCGGTGA-
TAATGACAAG) and hexon protein (hexon59: GCCGCA-
GTGGTCTTACATGCACATC and hexon39: CAGCACGCC-
GCGGATGTCAAAG).
Determination of viral replication in vitro
RWP-1, NP-18 and BxPC-3 cells were seeded at 3610
4 cells per
well in quadruplicate in 24-well plates and cultured overnight. The
next day, cells were infected with Adwt-RGD, AdRGDTat8-TK-
L or ICOVIR5-TK-L at 1610
4 vp per cell. Four hours post-
infection, the medium was replaced by complete fresh medium.
Twenty-four hours later the cells were incubated, either in the
presence or absence of 10 mg/ml GCV, for 3 days. Then the cells
and supernatants were collected and subjected to three cycles of
freeze and thawing. A549 cells were infected for 24 h, with serial
dilutions of total extracts, and the number of viral infective
particles was quantifed by means of the hexon protein-staining
technique.
Dose-response analysis and ID50 values
NP-18, RWP-1 and BxPC-3 cells were seeded in 96-well plates
at a density of 3610
3 cells per well in 96-well plates and cultured
overnight. Twenty-four hours later, the cells were infected with
Adwt-RGD, AdRGDTat8-TK-L or ICOVIR5-TK-L, using a
dose range of 0 to 10
6 vp/cell, in triplicates. Four hours post-
infection the viral medium was replaced by a complete fresh
medium. Twenty-four hours later the cells were incubated, either
in the presence or absence of GCV, for 3 days. Cell viability was
measured using the MTT colorimetric assay and ID50 values were
estimated from dose-response curves by standard non-linear
regression, using an adapted Hill Equation [15].
Tumour growth studies
BxPC-3 cells (2.5610
6) were injected s.c. into each posterior
flank of BALB/c nude mice (Charles River France, Lyon, France).
Tumours were measured three times per week and volumes were
calculated according to the formula V (mm
3)=larger diameter
(mm)6smaller diameter 2 (mm
2)/2. Treatment was initiated when
tumours achieved a mean volume of 50 mm
3. All animal
procedures met the guidelines of European Community Directive
86/609/EEC, and of the Local Catalan regulations (Law 5/1995,
Decrees 214/97, 32/2007) and were approved by the Local
Animal Care and Ethics Committee (CEEA-PRBB).
Determination of viral yield in tumors
Viral genomes were determined in tumor samples by a
quantitative PCR (qPCR) assay and SYBR
 Green chemistry
(Roche). DNA was isolated using a DNeasy Blood and Tissue Kit
(QIAGEN, Barcelona, Spain) according to the manufacturer’s
instructions. DNA concentration was determined spectrophoto-
metrically and adjusted to 10 ng/ml, 5 ml of DNA was used for
qPCR. A plasmid DNA ICOVIR5-TK-L was serially diluted (10–
10
6 copies, in a background of tumor genomic DNA) and used as a
quantification standard for the real time qPCR. A conserved
sequence of the adenovirus hexon gene was PCR amplified using
forward and reverse hexon primers described above. Samples and
standards were amplified in triplicate. Data were collected and
analyzed using a LightCyclerH 480 Real-Time PCR System
(Roche Diagnostics, Mannheim, Germany). The lower limit of the
linear range of the quantitative assay was determined to be 1000
adenovirus DNA copies in the background of tumor genomic
DNA. Results are expressed as viral genomes in one mg of tumor
DNA.
Viral infective particles in tumor samples were analyzed in
homogenates prepared in isotonic buffer, and subjected to three
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and the number of infectious particles were quantified by hexon
staining.
Radiolabeled substrate synthesis
All chemistry procedures were performed with HPLC grade
solvents obtained from Scharlab (Barcelona, Spain), Panreac
(Castellar del Valle `s, Spain) or Sigma-Aldrich (Madrid, Spain). All
chemicals were used without further purification and purchased
from Sigma-Aldrich, Fluka (Sigma-Aldrich, Madrid, Spain) and
Acros Organics (Thermo Fisher Scientific, Geel, Belgium). QMA
and Alummina Sep-pack were obtained from Waters (Milford,
MA), 0.22 mm filters from Millipore (Madrid, Spain) and 18-O
enriched water from Marshall Isotopes. An 18/9 IBA (Ion Beam
Application, Belgium) Cyclotron was used for [
18F
2]fluoride
production and an IBA FDG Synthesizer Module was used for
fluorination. Radioactivity was determined using a calibrated
chamber (Comecer, Pet Dose) HPLC for [
18F]FEAU purification
was carried out on a modular Agilent 1100 series HPLC system
with a semi-preparative reverse-phase C18 column (Agilent SB-18,
250610 mm, 5 mm) equipped with UV (l=254) and radioactive
detector (Raytest, Gita). For quality control, HPLC analysis was
carried out on a modular Agilent 1100 series system with a
reverse-phase C8 column (Agilent XDB-C8, 15064.6 mm, 5 mm)
equipped with diode-array UV (l=220 and 254) and radioactive
detector (Raytest, Gita).
Non-radioactive standard and precursor were synthesized
following published methodologies [20,21,22]. Full characteriza-
tion of both compounds was performed using MS and
1H-NMR.
[
18F]FEAU was obtained following published methodologies with
minor modifications [23,24]. Briefly, [
18F
2]fluoride was obtained
with 16 MeV protons irradiation of 18-O enriched water using the
nuclear reaction
18O(p,n)
18F, and trapped on a QMA cartridge.
[
18F]fluoride was then eluted using a solution of 28 mg Kryptofix
2.2.2 and 5 mg K2CO3 in a mixture of 700 ml of acetonitrile and
200 ml of water. The [
18F
2]fluoride solution was evaporated
azeotropically at 100uC using an helium stream and vacuum three
times with 1 ml of dry acetonitrile each. To the dry residue, a
solution of 6 mg of precursor (2-O-(trifluoromethylsulfonyl)-1,3,5-
tri-O-benzoyl-a-D-ribofuranose) in dry acetonitrile was added,
and the reaction mixture was heated at 80uC for 20 min. The
reaction mixture was cooled, passed through an alumina cartridge,
and eluted with 2.5 ml of ethyl acetate. The solvent was removed
applying a stream of nitrogen at 80uC. The residue was dissolved
in 0.4 ml dichloroethane under inert helium atmosphere and
100 ml of hydrogen bromide in acetic acid (30%) was added. The
reaction mixture was heated at 80uC for 10 min and evaporated
using a nitrogen stream at 50uC. The dry residue was mixed with a
fresh solution of 2,4-bis-O-(trimethylsilyl)thymidine (80 mmol in
0.5 ml dichloroethane). The mixture was then heated at 100uC for
60 min, cooled, passed through an alumina cartridge and eluted
with 2.5 ml of 10% of methanol in dichloromethane. The solvent
was evaporated using a nitrogen stream at 100uC. Then, the
residue was dissolved in 300 ml methanol and 30 ml of sodium
methoxide 1 M in methanol were added. This mixture was heated
at 80uC during 5 min. The reaction crude was cooled at room
temperature and HCl 2N was used. After neutralization the
solvent was evaporated. The residue was solved in a 10:90 mixture
of acetonitrile/water and purified by sempreparative HPLC at a
flow of 4 ml/min. The appropriate fraction eluted at about
20 min. After collection, it was evaporated until dryness, dissolved
in 0.9% saline solution and passed trough a 0.22 mm filter. An
aliquot of the final product was analyzed by analytical HPLC
using a mixture of acetonitrile/water 10:90 at a flow of 2 ml/min
and identified by co-elution of standard. [
18F]FEAU was obtained
in 1465% (n=5) decay corrected yield with a chemical and
radiochemical purity .97%.
In vitro
18F-FEAU uptake assay. To measure in vitro the TK
activity of adenovirus-transduced tumor cells after the different
treatments tested, an
18F-FEAU uptake assay was performed in
duplicates. The same amount of radioactivity (35 KBq aprox.) was
added to each well and cells were incubated at 37uC, 5% CO2 for
2 h. After this period, supernatants were removed and placed in a
series of tubes. Cells were washed once with fresh medium, which,
after removal, was transferred to a new series of tubes. Cells were
then trypsinized and centrifuged at 1200 rpm for 5 min. The
radioactivity in each of the three series of tubes was measured in a
Wallac 1470 Wizard gamma counter (PerkinElmer, Waltham,
MA). HSV1-TK activity was determined as a function of
18F-
FEAU uptake by referring the count values obtained from each
cellular pellet to those of a known standard.
MicroPET imaging. Mice bearing ICOVIR5TK-L-injected
xenografts in the anterior flanks were imaged for TK activity using
a microPET R4 (Concorde Microsystems, Knoxville, TN) and
18F-FEAU as a substrate for HSV1-TK enzyme. All animals were
fed ad libitum and had continuous access to water up to the time of
experiment. Mice were anesthetized with 1.5–2% isoflurane
(Isoflo, Esteve) in oxygen and injected via tail vein with 2–
4 MBq of
18F-FEAU two hours prior to a 12.5 min image
acquisition. Imaging was performed on a prone position using an
energy window of 350–650 keV and a coincidence timing window
of 6 nsec. The resulting list-mode data were sorted into 2D
histograms by Fourier re-binning and the images reconstructed by
filtered back-projection into a 1286128663 (0.8260.8261.3-mm)
matrix. The image data were corrected for non-uniformity of
response of the microPET, deadtime count losses, and physical
decay to the time of injection but no attenuation, scatter, or
partial-volume averaging correction was applied. Using a mouse-
size phantom, an empirically determined system calibration factor
(i.e. mCi/ml/cps/voxel) was used to convert voxel count rates to
activity concentrations. The resulting image data were processed
according to the software provided by the manufacturer and
quantification was obtained by region-of interest analysis (ASIPro,
Concorde Microsystems, Knoxville, TN).
Statistical Analysis
The descriptive statistical analysis was performed on SPSS
software (SYSTAT software, Inc, Chicago, IL). Results are
expressed as mean 6 SEM. A Mann-Whitney non-parametric
test was used for the statistical analysis (2-tailed) of in vitro and in
vivo studies. P,0.05 was taken as the level of significance.
Statistical analysis of in vivo tumour growth was performed by
ANOVA for repeated measures, employing the SPSS software.
Survival analyses were also performed to analyze time-to-event
probability using the SPSS software. The survival curves obtained
were compared for the different treatments. A log-rank test was
used to determine the statistical significance of the differences in
time-to-event. A p value of less than 0.05 was considered
statistically significant.
Results
GCV enhances the potency of ICOVIR5-TK-L in spite of
interference with viral replication
ICOVIR5-TK-L (Figure 1A) contains the Tat8-TK gene under
the control of the adenoviral Major Late Promoter and is
expressed as a splice variant from the IIIa splicing factor sequence
identically to AdRGD-Tat8-TK-L [1]. It differs from the
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of all the selective control elements from ICOVIR-5 [5].
To confirm the integrity of the virus, a panel of pancreatic
cancer cell lines were infected with ICOVIR5-TK-L at 1000 vp/
cell and further analyzed for expression of viral elements. mRNA
from cell lysates were extracted at 24 h post-infection and bands
corresponding to E2F-E1A junction fragment, E1A, hexon and
Tat8-TK mRNAs were obtained after RT-PCR analysis in every
cell line analyzed (Figure 1B).
To examine the cytopathic effect of ICOVIR5-TK-L on human
pancreatic adenocarcinoma cells, RWP-1, NP-18, and BxPC-3
cells were infected with increasing doses of adenovirus and cell
viability was analyzed after 4 days in culture, in the presence or
absence of the prodrug ganciclovir. Parental Adwt-RGD and the
AdRGDTat8-TK-L were included for comparison. MTT assays
showed that ICOVIR5-TK-L was able to induce cytotoxicity 3
days after culture albeit to a lesser extent than parental
adenoviruses, as evidenced by a shift to the right in the dose-
response curves corresponding to ICOVIR5-TK-L (Figure 2A).
ID50 values of ICOVIR5-TK-L in all three pancreatic tumor cell
lines were higher than those of the control viruses. Interestingly, in
ICOVIR5-TK-L infected cells the addition of GCV significantly
increased the cytotoxicity in all three cell lines, with ID50 values
lower in the combination of ICOVIR5-TK-L/GCV than in those
of ICOVIR5-TK-L treated alone This observation did not hold
true for the parental adenoviruses, as the only situation in which
the addition of GCV induced an increase in the cytotoxicity of the
parental adenoviruses was in BxPC-3 cells treated with AdRGD-
Tat8-TK-L (Figure 2B).
In order to evaluate whether the lower cytotoxicity induced
by ICOVIR5-TK-L as compared to parental adenoviruses was
related to a decreased ability to replicate, transducing units
resulting from infected cultures of RWP-1, BxPC-3 and NP-18
cells were quantified by hexon staining four days after in-
fection. In all three cellular contexts, ICOVIR5-TK-L infe-
ction yielded less infective particles than Adwt-RGD and
AdRGD-Tat8TK-L, differences being statistically significant
(Figure 2C Left).
Similarly, we decided to analyze the impact of GCV addition on
viral replication by measuring viral yield in cultures of RWP-1,
BxPC-3 and NP-18 cells infected with ICOVIR5-TK-L, grown in
presence of absence of GCV (Figure 2C Right). A significant
reduction in the quantity of infective units (up to 2-log for BxPC-3
cells) was observed for all three lines when GCV was added,
similarly to what we previously described by parental AdRGD-
Tat8TK-L [1].
Figure 1. ICOVIR5-TK-L. (A) Schematic representation of adenoviral genomic elements. The E1A-D24 gene was cloned under the control of the
E2F-1 promoter, preceded by an insulator sequence in the 59 region. The Tat8TK transgene was cloned downstream of L5 to be expressed as a part of
a polycystronic transcript, under the control of the Major Late Promoter. (B) Quality control assessment. The presence of E2F-1 promoter, and of
Hexon, E1A and Tat8TK genes was analyzed by RT-PCR in pancreatic cancer cells transduced with 1000 vp/cell of ICOVIR5-TK-L. A non-
retrotranscribed mRNA sample was used as a negative control for the PCR.
doi:10.1371/journal.pone.0026142.g001
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PLoS ONE | www.plosone.org 4 October 2011 | Volume 6 | Issue 10 | e26142Figure 2. ICOVIR5-TK-L cytotoxicity in vitro and replication. (A) Dose-response analysis of Adwt-RGD, AdRGDTat8TK-L and ICOVIR5-TK-L in
RWP-1, NP-18 and BxPC-3 cells, in presence (right) or absence (left) of 10 mg/mL GCV. Cells were incubated with the respective adenovirus during
4 hours. GCV treatment was initiated 24 hours postinfection and viability was measured by MTT 4 days postinfection. (B) ID50 values for each
condition calculated by non-linear regression. (C) Viral replication of Adwt-RGD, AdRGDTat8TK-L and ICOVIR5-TK-L in RWP-1, NP-18 and BxPC-3 cells
in the absence of GCV (left) Viral replication of ICOVIR5-TK-L in the presence or absence of GCV (right). Three 610
4 cells per well were infected with
10
4 vp per cell, during 4 hours. When stated GCV treatment (10 mg/mL) was initiated 24 hours postinfection. At day 4 postinfection, cells and
supernatants were harvested and the viral yield was determined by hexon protein staining. Results expressed as means of at least 3 independent
experiments +/2 SEM. *p,0.05, **p,0.01, ***p,0.001.
doi:10.1371/journal.pone.0026142.g002
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comparable to Adwt-RGD
A subcutaneous xenograft model consisting of BxPC-3 cells
implanted in the flanks of nude mice was used to evaluate the
antitumoral efficacy of ICOVIR5-TK-L, in comparison to an
RGD-pseudotyped wild type replication-competent adenovirus
Adwt-RGD. When tumors had reached an average volume of
50 mm
3 (day=0) mice were randomized into three groups (n=5)
receiving either a daily intratumoral dose of 2610
10 vp ICOVIR5-
TK-L per tumor on days 0, 1, 7 and 8 followed by a daily dose of
100 mg/kg GCV intraperitoneally (i.p) on days 4, 5, 6, 11, 12 and
13; or Adwt-RGD instead of ICOVIR5-TK-L. The third group
received intratumoral injections of saline instead of adenovirus. A
significant delay in tumor growth was observed in the two groups
receiving adenoviral treatment as compared to saline-treated
control group (Figure 3A). Noteworthy, no statistically significant
difference was observed between the two treated groups, suggesting
that despite the fact that ICOVIR5-TK-L presents a reduced ability
to replicate it can induce, when applied in combination with GCV,
a similar antitumor effect as a replicative adenovirus without tumor
specificity. Kaplan-Meier survival analysis showed a statistically
significant survival benefit for the two adenovirus-treated groups as
compared to saline group, (Log-Rank Test 0.0005 and 0.0023) but
no difference was observed between the two treated groups
(Figure 3A). These results demonstrate that ICOVIR5-TK-L/
GCV suicide gene virotherapy has an antitumoural potency similar
to that of the wild type adenovirus.
ICOVIR5-TK-L is a selective virus that replicates in cells with a
pRB deficient pathway. This selectivity brings the potential to use
this virus to target disseminated cancer. In order to assess whether
ICOVIR5-TK-L was also able to induce growth delay when
administered systemically, mice bearing BxPC-3 tumors were
treated with a single intravenous injection of ICOVIR5-TK-L
5610
10 vp and two rounds of three consecutive doses of GCV
(100 mg/Kg) at days 4,5,6 and 11,12,13 after viral injection.
ICOVIR5-TK-L/GCV treatment induced a significative tumour
growth inhibition, when compared to saline injected tumours
(Figure 3B). Kaplan-Meier survival analysis revealed a median
survival time of 6 days in control animals and of 13 days in
ICOVIR5-TK-L/GCV treated mice (Log Rank Test=0.0084)
(Figure 3B).
ICOVIR5-TK-L are detected by PET imaging in injected
and contra-lateral tumors
First, we conducted a series of experiments with the recombi-
nant adenovirus AdTK and AdTat8TK to demonstrate the
detectability of the nucleoside analogue
18F-FEAU upon phos-
phorylation by the TK enzyme.
18F-FEAU is an optimal
radiotracer to monitor TK activity as it has been reported to
present high uptake rate and low background activity [24]. To this
end, NP-18 pancreatic tumor cells were transduced with
increasing AdTK or AdTat8TK viral doses and 24 h later
incubated with 33.34 MBq of
18F-FEAU for 2 h. A similar viral
dose dependent effect was observed by quantification of cellular
radioactivity (Figure S1A). In vivo
18F-FEAU tumor retention was
first monitored in s.c tumors derived from CWR-CLT cells stably
expressing the TK gene (Figure S1B). In another set of
experiments, 2610
10vp of recombinant AdTK were intratumo-
rally injected into BxPC-3 xenografts. MicroPET imaging with
18F-FEAU was performed 5 days later. Accumulation of entrapped
radiotracer was detected both in the injected tumor and in the
liver, most probably as a consequence of the blood flow and the
strong liver tropism of adenovirus (Figure S1C).
To study the feasibility of detecting the presence of the oncolytic
ICOVIR5-TK-L non-invasively in vivo by PET scans, BxPC-3
xenografts were generated in the anterior flanks of nude mice.
Once the tumors reached 200 mm
3 in size, 2610
10vp of
ICOVIR5-TK-L were injected into the right-flank tumor.
18F-
FEAU was i.v. injected 2 h previous to image acquisition. Images
obtained at 3, 4 and 5 days after viral injection showed tumor
specific detection. Interestingly, both injected and contra-lateral
non-injected tumors were positive for the radiotracer. High levels
of radioactivity were also observed in the gallbladder and kidneys,
as renal clearance was the major route of elimination for the
radiotracer (Figure 4A). Quantification of
18F-FEAU activity in the
tumor areas revealed a significant increase in radioactive counts in
the injected tumors both at 4 and 5 days after injection and
although at lower levels
18F-FEAU activity was also significantly
increased in the contra-lateral tumors (Figure 4B). Viral presence
in the contra-lateral tumor was confirmed by detection of the
hexon viral gene in tumor DNA extracts (Figure 4C).
TK activity from PET scans correlates with the antitumoral
effects in the different regimens of ICOVIR5-TK-L/GCV
treatment
We have previously shown that the combination protocol of a
replicative competent adenovirus and GCV can display different
outputs in terms of its antitumoral effects [1]. In the current work
we have investigated the antitumor efficacy of ICOVIR5-TK-L
and its combination with GCV under different regimens. BxPC-3
xenografts were intratumorally injected with four doses of 2610
10
vp of ICOVIR5-TK-L. Mice were randomized in three treated
groups. Group A received two consecutive viral doses followed by
three doses of GCV in two cycles. Group B received four
consecutive viral doses followed by 6 doses of GCV. Group C
received the four viral doses in two cycles, similarly to group A but
without GCV. An effective antitumoral effect was observed in the
group treated with protocol A that received virus and GCV in two
cycles. Two weeks after treatment tumor size in control mice was
2.3-fold higher than tumors from treatment A (p,0.05).
Furthermore, treatment A was more effective than treatments B
and C (p,0.05) (Figure 5A). Interestingly quantification of TK
activity, as measured by
18F-FEAU retention in PET scans of
injected tumors revealed that treatment A and C had similar
values significantly superior to those of treatment B, suggesting
that GCV could be interfering in viral replication in the B protocol
(Figures 5B, 5C). In fact tumor viral titers were slightly reduced
when GCV was applied. However this was observed in the two
conditions of GCV administration, protocols A and B (Figure 5D).
The apparent discrepancy of elevated TK activity and reduced
viral titers, might partially result from the 24 h delay observed
between TK expression and viral release in infected cells (Figure
S2), indicating that there is a population of cells that do express
TK but are not yet producing viruses. Such cells, at higher GCV
concentrations, as can be expected in protocol B would be rapidly
eliminated resulting in reduced TK activity, whereas at lower
GCV, as expected in protocol A they might survive.
Overall these results show that the combined effects of armed
TK oncolytic ICOVIR5-TK-L and GCV can provide with
improved antitumoral effects under an appropriate administration
schedule.
Discussion
Oncolytic adenoviruses have shown antitumoral effects and
proven to be relatively safe in the clinics [25]. However, tumor
response is suboptimal highlighting the need of enhanced potent
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viral replication and distribution in multiple organs are absolutely
necessary to correlate vector design and dose schedule with
specificity of infection and antineoplastic efficacy.
We have previously demonstrated that the combined therapy
of adenoviral replication and TK/GCV cytotoxicity triggers
enhanced antitumoral effects that either therapy alone under a
defined regimen of virus and GCV [1]. Here we report that
GCV increases the cellular killing effect of a pRB pathway-
based selective adenovirus armed with the TK gene (ICOVIR5-
TK-L) inducing a similar antitumor response of a highly non-
selective replicating adenoviruses and shows its potential to act
at distant tumor areas. Our data suggests that GCV can boost
the anti-cancer effects of armed adenovirus in the context of
attenuated viral oncolysis. In fact, ICOVIR5TK-L viruses
showed both reduced lytic activity and viral production when
compared to the replication-competent AdRGDTat8TK-L,
probably related to the larger size of ICOVIR5-TK-L genome.
In this direction it is well known that Ad5 capacity to carry
exogenous DNA is restricted and the insertion of transgenes into
Figure 3. In vivo antitumor effect of ICOVIR5-TK-L+GCV administered locally or systemically. (A) Nude mice bearing BxPC-3
subcutaneous xenografts were treated with saline, Adwt-RGD or ICOVIR5-TK-L+GCV as indicated in the diagram. Tumor volumes were measured
every other day during 2 weeks. Adwt-RGD and ICOVIR5-TK-L+GCV induced a statistically significant delay in tumor progression as compared to
saline-treated controls. No significant difference was observed between Adwt-RGD and ICOVIR5TK-L+GCV treatments. Kaplan-Meier survival analysis
showed a statistically significant increase in median survival of mice receiving Adwt-RGD and ICOVIR5-TK-L as compared to saline treated controls. (B)
Antitumor effect of a single iv dose/mouse of 5610
10 vp ICOVIR5-TK-L followed by 6 doses of GCV administered as indicated in the diagram.
Statistically significant tumor growth delay and increase in median survival was observed in treated animals as compared to controls. Volumes
expressed as fold increase from volume at day 0 (V0). Results expressed as means +/2 SEM (n=5 mice/group). *p,0.05, **p,0.01.
doi:10.1371/journal.pone.0026142.g003
Tracing ICOVIR5-TK-L Antitumor Effects by PET
PLoS ONE | www.plosone.org 7 October 2011 | Volume 6 | Issue 10 | e26142the adenovirus genome can limit the oncolytic potency of the
virus [26]. Interestingly, GCV improved the oncolytic capacity
of ICOVIR5-TK-L in spite of interfering with viral replication,
triggering similar cell death and antitumor effects in s.c xeno-
grafts as wild type adenoviruses. These suggest that a lower viral
load of ICOVIR5-TK-L generated in infected cells might prove
as beneficial as Adwt-RGD when GCV is administered. This
might provide enhanced safety to the oncolytic ICOVIR5-TK-L
virus by minimizing potential adverse events associated with
viral replication in non-desired tissues.
Figure 4. In vivo detection of TK activity using
18F-FEAU as a PET radiotracer. (A) 2-D slices showing an increased retention of radiotracer in
injected (I) and in non-injected (NI) contralateral tumors. (B) Volumes of Interest (VOI) corresponding to tumoral masses were defined and
18F-FEAU
activity was measured. At days 4 and 5 activity was higher than background signal measured in the toracic cavity, being the difference statistically
significant, both in injected and also in non-injected contralateral tumors. (C) Presence of ICOVIR5-TK-L in non-injected tumors was confirmed by
detection of the viral hexon gene, in tumoral tissue. N: tumor from a non-injected naı ¨ve mouse. C+: positive control of PCR reaction. *p,0.05.
doi:10.1371/journal.pone.0026142.g004
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PLoS ONE | www.plosone.org 9 October 2011 | Volume 6 | Issue 10 | e26142Furthermore, our results demonstrate that viral activity can be
monitored in a preclinical experimental model of pancreatic
cancer by non-invasive PET imaging. We could trace TK activity
of the replication-competent ICOVIR5-TK-L intratumorally
injected in BxPC-3 xenografts at doses of 2610
10 vp. To our
knowledge this is the first demonstration of monitoring a TK
replication competent adenovirus in a tumor. Previous data in
hepatocellular carcinoma was reported in recombinant TK
adenovirus in primates and in humans [10,12,27]. The biochem-
ical attributes of high uptake rate and selectivity of the
18F-FEAU
substrate could certainly contribute to facilitate monitoring TK
expression in vivo [28]. This high sensitivity by the PET substrate
allowed for the detection of TK activity in the liver after
intratumoral injection of a non-replicative TK expressing
adenovirus. This viral leakness could probably result from
bloodstream spreading of the virus in this pancreatic tumor
model, in which s.c. xenografts are highly vascularized. This might
imply that intratumoral injections of a TK therapeutic virus in this
model could act at distant metastasis, or at least at liver tumoral
focus, an organ where pancreatic tumors frequently metastasize.
Non-invasive imaging of a replication competent adenovirus has
been nicely shown in prostate cancer and in colorectal cancer cells
by monitoring the sodium iodide symporter (NIS) by SPECT
imaging [29,30,31]. Thus, both technologies TK/PET and NIS/
SPECT can be effectively used to monitor replication competent
adenovirus in the body. Interestingly, TK monitoring in a
replicative adenovirus administration followed by GCV treatment
could also provide information on the treatment response, as we
observed in the current work an association of the TK activity and
the administration regimen of virus plus GCV with the antitumor
effect.
An advantage of oncolytic suicide gene therapy with TK-armed
oncolytic adenoviruses is that the toxic products produced within
the tumor can reach cells that have not been infected, by the so-
called bystander effect increasing tumor cell destruction. Despite
GCV reducing total viral load the TK/GCV effects compensate
on the reduced lytic activity and the final outcome is beneficial.
Although a considerable delay on tumor progression was
achieved by ICOVIR5-TK-L+GCV, combination treatment
failed to induce complete erradication of pre-established BxPC-3
tumors; and although it doubled mean survival, long-term survival
of treated mice was not achieved. This might be related to the
suboptimal spreading of viral particles within the tumor mass in
rapidly growing tumors as are BxPC-3 xenografts. The redesign of
adenoviruses incorporating mutations with replication enhance-
ment capacity or engineering adenoviruses that could act on the
tumor stroma could facilitate intratumoral viral spread and
potentially increase long-term survival. To improve the in vivo
antitumoral effect of the proposed treatment, the combination
with strategies that can prime an effective anti-tumor immune
response is especially appealing. Immunotherapy and cytotoxic
combinations can become more specific and more effective. In
fact, in the context of an immunocompetent environment, the
oncolytic suicide TK/GCV therapy could potentially act as an
enhancer of immunogene therapy. In this direction it has recently
been shown that the administration of a recombinant adenovirus
AdTK along with ganciclovir in immunocompetent mice bearing
tumors, plus a chemotherapy regimen of cisplatin and gemcitabine
induced marked and significant regression, similar to that achieved
with the injection of Ad-INF-a or Ad-E7, an adenovirus
expressing the E7 protein of the human papillomavirus, under
the same chemotherapy combined treatment. This major effect
was demonstrated to be due to a boost effect that chemotherapy
would trigger after being primed with AdTK/GCV [32].
Although we did not directly evaluate the immunological response
to ICOVIR-5TK-L, due to the low permissibility of murine cells
to Ad5 replication, there are several reports showing that AdTK/
GCV in vivo causes cell death directly and through induction of an
antitumoral or antiviral immune response [33,34]. Consistent with
these data ICOVIR5-TK-L/GCV, through its ability to replicate
in the tumors might enhance the vaccine effect and an appropriate
GCV regimen will provide with the chemotherapeutic effect. We
could then speculate that treating patients with ICOVIR5TK-L/
GCV could have similar effects to a combined approach of
immunotherapy and chemotherapy with the advantage of
avoiding the systemic toxicity commonly associated with chemo-
therapy.
Treatment-related toxicity is an important consideration when
developing a new cancer therapy. The safety of replication-
competent adenovirus mediated suicide therapy has been
evaluated in Phase I/II trials of prostate cancer and shown low
toxicity [30]. Importantly, ICOVIR5-TK-L/GCV might even
have reduced toxicity. Although the side effects of GCV could not
be avoided, those seem to be restricted to the hematologic lineages
with mild lymphopenia being the most prevalent. Viral toxicity is
expected to be minimal thanks to the high level of tumor selectivity
of ICOVIR5-TK-L. The different genetic modifications present in
the viral backbone designed to avoid E1A expression and
subsequent virus replication in normal cells are a guarantee of
safety [5].
In summary, our results indicate that the expression of the TK
gene in an oncolytic adenovirus can be monitored in vivo by PET
imaging allowing for the traceability of the virus in the body.
Moreover, the oncolytic suicide gene therapy based on the TK/
GCV system triggers considerable antitumoral effects under an
appropriate regimen. Therefore the application of ICOVIR5TK-
L/GCV in pancreatic tumors holds the potential to be transferable
to patients.
Supporting Information
Figure S1 Analysis of TK activity by
18F-FEAU substrate.
(A) NP-18 pancreatic cancer cells were transduced at the indicated
Figure 5. Effects of administration regimen on antitumor activity, TK activity and viral replication. (A) BxPC-3 subcutaneous xenografts
were generated in nude mice that were randomized in three groups, receiving different treatments. Group A received 4 doses of 2610
10 vp ICOVIR5-
TK-L on days 0, 1, 7 and 8, and 6 ip doses of 100 mg/kg GCV on days 4, 5, 6, 11, 12 and 13. Group B received 4 doses of 2610
10 vp ICOVIR5-TK-L on
days 0, 1, 2, 3 and 6 ip doses of 100 mg/kg GCV on days 6, 7, 8, 9, 10 and 11. Group C received ICOVIR5TK-L as in Group A, and 6 ip injections of saline
instead of GCV. A fourth group receiving saline intratumorally and ip was used as a control. Tumor volumes were measured and expressed as fold
increase at day 14 from day 0. (B) PET images at day 14 showing specific retention of radiotracer in tumors. (R) Right tumor, (L) Left tumor. (C)
Quantification of TK activity in tumors. GCV treatment induced a decrease in
18F-FEAU retention when administered as in Group B, but not as in
group A, when compared to the group receiving only adenovirus. (D) Quantification of ICOVIR5-TK-L transducing units in injected tumors. Xenografts
were excised at day 14 and homogenized in isotonic buffer. Extracts were applied to A549 cells and the number of infectious particles in the extracts
were quantified by Hexon staining. GCV treatment produced a significant decrease in the number of ICOVIR5-TK-L transducing units regardless of the
protocol applied (A or B) (left panel). (D) Q-PCR analysis of viral genomes in tumors. A reduction in viral genomes was also observed in those tumors
that were treated with GCV (right panel). *p,0.05, **p,0.01.
doi:10.1371/journal.pone.0026142.g005
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PLoS ONE | www.plosone.org 10 October 2011 | Volume 6 | Issue 10 | e26142viral doses. Twenty-four hours later cells were incubated with
0,91 mCi of
18F-FEAU for 2 h and radioactivity was quantified in
the cell extracts. (B) Tumors from CWR-CLT cells stably
expressing the TK gene were s.c. injected into the flanks of nude
mice.
18F-FEAU tumor retention was analyzed as described in
materials and methods. Images show specific signal in the tumor.
(C) Mice bearing BxPC-3 xenografts received three intratumoral
injections of 2610
10 vp/tumor AdTK. Five days later
18F-FEAU
retention was analyzed. Images show TK activity in the tumor and
strong signal in the liver.
(TIF)
Figure S2 Virus release and TK expression. HEK 293
cells were seeded at 2610
5 cells per well in triplicate in 24-well
plates and cultured overnight. The next day, cells were infected
with ICOVIR5-TK-L at 1610
3 vp per cell. Four hours later,
infection medium was removed and cells were washed three-times
with PBS and incubated with fresh medium. (A) At the indicated
time points a fraction of the supernatant was harvested and viral
yield was determined by the anti-hexon staining method.
Detection of viral particles became evident at 48 h post-infection.
(B) RT-PCR analysis was performed to determine TK and E1A
expression in RNA extracted from cell pellets at the indicated
time-points. E1A and TK were first detected at 6 h and 24 h post-
infection respectively.
(TIF)
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